GSK discontinued development of camlipixant, a P2X3 antagonist acquired in a $2 billion deal, after mixed Phase 3 results in refractory chronic cough. The first Phase 3 study met its primary endpoint at week 12, but failed at week 24 in the second study, and neither study cleared several chronic cough diary secondary measures. GSK characterized the efficacy as limited and said it is unlikely to transform patient care. The company’s decision closes out a respiratory asset story investors had been watching as a potential catalyst. Trevi Therapeutics’ Haduvio (oral nalbuphine ER) was reported as a beneficiary, highlighting how clinical trial outcomes can reallocate the competitive landscape quickly in high-priority indications like chronic cough.